# Anthony M. Joshua

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/anthony-m-joshua/

## Facts

| Field | Value |
| --- | --- |
| Citations | 31,515 |
| Field | Prostate Cancer Treatment and Research |
| h-index | 70 |
| i10-index | 225 |
| Last Known Institution | Garvan Institute of Medical Research |
| OpenAlex ID | https://openalex.org/A5085333470 |
| ORCID iD | https://orcid.org/0000-0001-5159-4580 |
| Works | 797 |

## Researcher papers

- [Enzalutamide in Metastatic Prostate Cancer before Chemotherapy](https://scholariq.org/papers/enzalutamide-in-metastatic-prostate-cancer-before-chemotherapy/)
- [Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer](https://scholariq.org/papers/enzalutamide-with-standard-first-line-therapy-in-metastatic-prostate-cancer/)
- [\[177Lu\]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial](https://scholariq.org/papers/177lu-lu-psma-617-versus-cabazitaxel-in-patients-with-metastatic-castration/)
- [Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma](https://scholariq.org/papers/overall-survival-benefit-with-tebentafusp-in-metastatic-uveal-melanoma/)
- [PSMA and FDG-PET as predictive and prognostic biomarkers in patients given \[177Lu\]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial](https://scholariq.org/papers/psma-and-fdg-pet-as-predictive-and-prognostic-biomarkers-in-patients-given-177lu/)
- [Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma](https://scholariq.org/papers/three-year-overall-survival-with-tebentafusp-in-metastatic-uveal-melanoma/)
- [Overall survival with \[177Lu\]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial](https://scholariq.org/papers/overall-survival-with-177lu-lu-psma-617-versus-cabazitaxel-in-metastatic/)
- [\[177Lu\]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial](https://scholariq.org/papers/177lu-lu-psma-617-plus-enzalutamide-in-patients-with-metastatic-castration/)

## Researcher topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Garvan Institute of Medical Research](https://scholariq.org/institutions/garvan-institute-of-medical-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.